Details of the Drug

General Information of Drug (ID: DMGMNUE)

Drug Name
AM0010
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 3 [1]
Pancreatic ductal carcinoma 2C10.0 Phase 3 [2]
Non-small-cell lung cancer 2C25.Y Phase 1 [3]
Renal cell carcinoma 2C90 Phase 1 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Cross-matching ID
TTD ID
D03MYX
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pancreatic cancer
ICD Disease Classification 2C10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-10 (IL10) DTT IL10 1.07E-02 0.08 0.56
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of ARMO BioSciences.